ACADIA PHARMACEUTICALS INC (ACAD) Form 10-Q — Aug 4, 2026
Acadia Pharmaceuticals reported Q2 2026 net product sales of $308.0 million, up 16.4% from $264.6 million a year earlier, with net income of $31.5 million and diluted EPS of $0.18 versus $0.16. NUPLAZID contributed $183.1 million and DAYBUE products $124.8 million of quarterly revenue. The balance sheet strengthened materially: cash and cash equivalents more than doubled to $385.0 million from $177.7 million at year-end 2025, alongside $571.5 million in available-for-sale investment securities, and six-month operating cash flow reached $134.8 million.
Key figures
- Eps
- 0.18
- Revenue
- 307959000
- Net Income
- 31500000
- Revenue Yoy
- +16.4% (Q2 2026 vs Q2 2025)
- Total Assets
- 1742900000
- Cash Position
- 384985000
- Shares Outstanding
- 172305518
- Q2 sga expense
- 160252000
- Six month revenue
- 576021000
- Nuplazid q2 revenue
- 183132000
- Six month net income
- 35137000
- Six month diluted eps
- 0.2
- Total stockholders equity
- 1306609000
- Daybue products q2 revenue
- 124827000
- Six month operating cash flow
- 134762000
- Potential milestone obligations
- up to $3.6 billion in the aggregate for pipeline candidates
- Q2 research and development expense
- 81555000
- Investment securities available for sale
- 571489000
Price after filing
Close on the filing date to close N calendar days later (from $26.55). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.